- Home
- FTAI vs RPRX Comparison
FTAI vs RPRX Comparison
Compare FTAI & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FTAI
- RPRX
- Stock Information
- Founded
- FTAI 2011
- RPRX 1996
- Country
- FTAI United States
- RPRX United States
- Employees
- FTAI N/A
- RPRX N/A
- Industry
- FTAI Misc Corporate Leasing Services
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- FTAI Industrials
- RPRX Health Care
- Exchange
- FTAI Nasdaq
- RPRX Nasdaq
- Market Cap
- FTAI 15.5B
- RPRX 15.6B
- IPO Year
- FTAI 2015
- RPRX 2020
- Fundamental
- Price
- FTAI $174.04
- RPRX $35.64
- Analyst Decision
- FTAI Strong Buy
- RPRX Strong Buy
- Analyst Count
- FTAI 12
- RPRX 3
- Target Price
- FTAI $184.92
- RPRX $45.33
- AVG Volume (30 Days)
- FTAI 1.1M
- RPRX 4.1M
- Earning Date
- FTAI 10-27-2025
- RPRX 11-05-2025
- Dividend Yield
- FTAI 0.69%
- RPRX 2.47%
- EPS Growth
- FTAI N/A
- RPRX 54.86
- EPS
- FTAI 4.05
- RPRX 2.32
- Revenue
- FTAI $2,142,930,000.00
- RPRX $2,305,243,000.00
- Revenue This Year
- FTAI $49.98
- RPRX $35.01
- Revenue Next Year
- FTAI $17.64
- RPRX $3.14
- P/E Ratio
- FTAI $43.17
- RPRX $15.33
- Revenue Growth
- FTAI 55.95
- RPRX 3.02
- 52 Week Low
- FTAI $75.06
- RPRX $24.05
- 52 Week High
- FTAI $181.64
- RPRX $38.00
- Technical
- Relative Strength Index (RSI)
- FTAI 78.29
- RPRX 45.51
- Support Level
- FTAI $160.00
- RPRX $34.84
- Resistance Level
- FTAI $167.49
- RPRX $36.94
- Average True Range (ATR)
- FTAI 5.33
- RPRX 0.84
- MACD
- FTAI 1.00
- RPRX -0.09
- Stochastic Oscillator
- FTAI 95.60
- RPRX 48.79
About FTAI FTAI Aviation Ltd.
FTAI Aviation Ltd is a aerospace company .It owns and maintains commercial jet engines with a focus on CFM56 engines. FTAI owns and leases jet aircraft which often facilitates the acquisition of engines at attractive prices. It invests in aviation assets and aerospace products that generate stable cash flows with the potential for earnings growth and asset appreciation.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.